Baicalein for Stage IV Cancer

Also known as: 5,6,7-Trihydroxyflavone, Scutellaria baicalensis extract

Baicalein inhibits multiple cancer pathways including 12/15-LOX, NF-κB, and PI3K while inducing ferroptosis in cancer cells.

Mechanism of Action

Baicalein promotes ferroptosis in cancer cells (iron-dependent lipid peroxidation death), inhibits 12/15-LOX-mediated pro-tumorigenic signaling, suppresses NF-κB/STAT3, and inhibits cancer stem cell self-renewal through Wnt pathway modulation.

General mechanism: Flavone from Scutellaria. 12/15-LOX inhibitor, α-synuclein aggregation inhibitor, ferroptosis modulator, Nrf2 activator.

Current Evidence

Preclinical evidence for multiple cancer types. Ferroptosis induction is a novel anti-cancer mechanism. Combination with standard therapy explored.

Clinical Status: Preclinical. Ferroptosis-inducing mechanism under active investigation.

Safety Profile

Safe. Traditional medicine use. GI effects possible. May interact with iron metabolism at high doses.

Key Research Questions

View glossary entry →

← Back to Stage IV Cancer Research